Current Prospects for Adrenocortical Carcinoma Pharmacotherapy

Area of Science:

• Endocrinology
• Oncology
• Genetics

Background:

• Adrenocortical carcinoma (ACC) is a rare, aggressive endocrine malignancy often diagnosed at advanced stages.
• Current treatments for ACC have shown limited efficacy, leading to poor patient prognosis.
• There is a critical need for novel and more effective therapeutic strategies for ACC.

Purpose of the Study:

• To review current adrenocortical carcinoma management.
• To explore emerging pharmacotherapy prospects for ACC.
• To highlight the potential of personalized medicine in ACC treatment.

Main Methods:

• Literature review of current ACC management.
• Analysis of novel therapeutic approaches including targeted therapy, immunotherapy, and theranostics.
• Discussion of next-generation sequencing for personalized ACC treatment.

Main Results:

• Standard ACC therapies have not significantly improved outcomes.
• Targeted therapies, immunotherapy, and theranostics show promise for ACC treatment.
• Next-generation sequencing enables identification of specific genetic profiles for tailored therapies.

Conclusions:

• Adrenocortical carcinoma remains a challenging diagnosis with a poor prognosis.
• Novel therapeutic strategies are crucial for improving ACC patient outcomes.
• Personalized medicine, guided by genetic profiling, represents the future of ACC treatment.